Lycera and Merck Reach Milestone in Collaboration for IBD Therapy

Lycera and Merck Reach Milestone in Collaboration for IBD Therapy
LyceraLycera Corp. has reached a milestone in its collaboration agreement with Merck on the study and development of small molecule therapeutic candidates to address a series of immune-mediated disorders, including inflammatory bowel diseases (IBD). Both companies believe that the milestone is a sign of the success of their partnership, which will continue conducting clinical investigations. Lycera has disclosed another payment, whose value was not publicly announced, from Merck. According to a press release from Lycera, the program that the two companies are working on together was initiated in February 2013 and includes Lycera's pipeline drug for IBD treatment, called LYC-30937. "We are pleased to announce the achievement of this milestone with our collaborator Merck," said the president and CEO of Lycera, Paul Sekhri. "The progress of the program provides further validation of Lycera's leadership in modulating immune responses to treat diverse disease indications with compelling unmet needs."merck The agreement established by the two companies determined an upfront p
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *